Blogs

Lead optimization gets more honest the moment you stop treating the seed as sacred.

That is the next thing one of our lorazepam-centered workflows forces into view.

In that dominance analysis, the seed is beaten by 33 descendants on the seven-way tradeoff surface, and 21 of those better molecules already sit on the top tradeoff layer. The blunt reading is simple: the starting molecule is not the best place to end.

But the sharper result comes when similarity constraints are added back in.

Those better molecules disappear quickly as the chemistry is forced to stay too close to the original scaffold neighborhood. On a standard fingerprint-similarity measure, only 14 remain at >= 0.15. At >= 0.20, only 5 remain. At >= 0.25, only 1 remains. By >= 0.30, there are 0.

That is commercially important because teams often protect the seed for understandable reasons. It feels safer, easier to defend internally, and more medicinally conservative. But this workflow shows that the better region can easily sit outside the tiny edit radius where the organization feels comfortable.

So a useful workflow has to do more than say “here are analogs that beat the seed.” It has to separate two different budgets.

One budget is for local polishing: stay close, validate the neighborhood, see what can be improved without moving far.

The second budget is for meaningful exploration: go farther from the seed when the evidence says that is where the better multi-objective region actually lives.

That split is easier to see visually:

That is a more mature optimization posture. It accepts that interpretability, organizational comfort, and objective improvement do not always point to the same place.

It also reinforces why the deliverable should be a report rather than a score dump. A report can say: local edits look safe but limited; the stronger region requires a wider move; here is the evidence for each; here is the reason not to confuse one with the other.

At this point, one fair objection remains. Maybe this is all just a clever story around one seed and one template.

The pooled seven-seed analysis is the answer to that objection.

Next in the series: when seven benzodiazepine lineages are merged into one panel, the same tradeoff-and-caveat logic starts to look less like an anecdote and more like a reusable decision framework.